REJO MULTI Unveiled at InterTabac 2025, Featuring Dual-Heating and Cross-Brand Compatibility
19.9.2025 10:00:00 CEST | Business Wire | Press Release
REJO, a global heat-not-burn (HNB) pioneer, officially unveiled REJO MULTI device at InterTabac 2025 as one of the exhibition’s most anticipated products. The device introduces a dual-heating system that pairs AirFlow and Round Heating technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919713971/en/
REJO MULTI Product Launch Event
“REJO MULTI represents a major step forward in HNB technology,” said Loic Li, the Global Sales Director of REJO. “Its open compatibility allows users to explore multiple brands and flavors with a single device, while our dual-heating system ensures even heating, enhanced aroma delivery, and consistent nicotine satisfaction.”
“Our goal with REJO MULTI is to empower users with choice and flexibility, while providing retailers and partners with an innovative, market-ready product that elevates the smoking alternative experience,” said Tibor Braun, the Western Europe Manager of REJO. “This launch underscores REJO’s commitment to open innovation and collaborative growth in the European market and beyond.”
The device incorporates advanced thermal control algorithms, an optimized power management system, and a lightweight, portable design at 82 grams. Users can benefit from up to 40 stick sessions per charge, with preheating achieved in under 20 seconds, offering convenience for daily use. The REJO MULTI is available in Twilight Purple, Aurora Green, and Luminous Grey, with a global launch scheduled for November 2025.
User benefits include:
- Flexibility: One device supports multiple brands, giving consumers freedom to select preferred flavors and smoking alternative experiences.
- Efficiency: Dual-heating technology maximized aroma and cloud production while reducing overall tobacco consumption by enabling two sessions per stick in round-heating mode.
- Portability: Lightweight and ergonomic design ensures ease of use in any setting.
European Expansion and Regulatory Readiness
2025 has been a milestone year for REJO’s European expansion. The company introduced its innovative portfolio - including TOZE herbal sticks, the REJO HS40 heating device, and advanced FARSTAR NSCs technology - to key markets such as Switzerland and Germany. TOZE sticks, inspired by East Asia’s tea-based tradition, pair seamlessly with the REJO HS40 to deliver consistent, high-quality flavor experience.
REJO has secured essential European regulatory approvals, reinforcing readiness to compete in the HNB market.
Community Engagement and REJO Club
Beyond product innovation, REJO continues to cultivate its REJO club, integrating online and offline community experiences. Following the success of the TENSION event in Switzerland, REJO aims to deepen global engagement through ongoing events, local support, and collaborative partnerships.
At InterTabac, REJO’s R&D Director participated in a forward-looking panel, highlighting the company’s commitment to innovation and industry leadership under its guiding principle: "Stay Courageous. Be Undefined."
A New Invitation: Take a Break. Take REJO.
REJO MULTI is more than a device - it represents a commitment to user choice, convenience, and advanced HNB technology. Through open compatibility, collaborative partnerships, and bold innovation, REJO is redefining how consumers engage with HNB products across global markets.
About REJO
REJO is a global provider of heat-not-burn (HNB) solutions, focused on delivering innovative, reliable, and open product options. Through collaboration with partners and its global community, REJO empowers users to break free from restrictive brand or flavor limitations and explore a broader range of experiences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250919713971/en/
Contacts
Media Contact:
Email: Newsroom@rejonow.com
Website: www.rejonow.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.rejonow.com
&esheet=54326768&newsitemid=20250919713971&lan=en-US&anchor=www.rejonow.com&inde
x=1&md5=f0ddf4315559534d950552fa9c271946
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom